276 related articles for article (PubMed ID: 25051439)
1. Genetic rescue of glycosylation-deficient Fgf23 in the Galnt3 knockout mouse.
Ichikawa S; Gray AK; Padgett LR; Allen MR; Clinkenbeard EL; Sarpa NM; White KE; Econs MJ
Endocrinology; 2014 Oct; 155(10):3891-8. PubMed ID: 25051439
[TBL] [Abstract][Full Text] [Related]
2. A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.
Ichikawa S; Austin AM; Gray AK; Econs MJ
J Bone Miner Res; 2012 Feb; 27(2):453-60. PubMed ID: 22006791
[TBL] [Abstract][Full Text] [Related]
3. Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression.
Ichikawa S; Sorenson AH; Austin AM; Mackenzie DS; Fritz TA; Moh A; Hui SL; Econs MJ
Endocrinology; 2009 Jun; 150(6):2543-50. PubMed ID: 19213845
[TBL] [Abstract][Full Text] [Related]
4. Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice.
Clinkenbeard EL; Farrow EG; Summers LJ; Cass TA; Roberts JL; Bayt CA; Lahm T; Albrecht M; Allen MR; Peacock M; White KE
J Bone Miner Res; 2014 Feb; 29(2):361-9. PubMed ID: 23873717
[TBL] [Abstract][Full Text] [Related]
5. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice.
Farrow EG; Yu X; Summers LJ; Davis SI; Fleet JC; Allen MR; Robling AG; Stayrook KR; Jideonwo V; Magers MJ; Garringer HJ; Vidal R; Chan RJ; Goodwin CB; Hui SL; Peacock M; White KE
Proc Natl Acad Sci U S A; 2011 Nov; 108(46):E1146-55. PubMed ID: 22006328
[TBL] [Abstract][Full Text] [Related]
6. A Mutation in the Dmp1 Gene Alters Phosphate Responsiveness in Mice.
Ichikawa S; Gerard-O'Riley RL; Acton D; McQueen AK; Strobel IE; Witcher PC; Feng JQ; Econs MJ
Endocrinology; 2017 Mar; 158(3):470-476. PubMed ID: 28005411
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic role of Fgf23 in Dmp1-null mice.
Liu S; Zhou J; Tang W; Menard R; Feng JQ; Quarles LD
Am J Physiol Endocrinol Metab; 2008 Aug; 295(2):E254-61. PubMed ID: 18559986
[TBL] [Abstract][Full Text] [Related]
8. The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency.
Bai XY; Miao D; Goltzman D; Karaplis AC
J Biol Chem; 2003 Mar; 278(11):9843-9. PubMed ID: 12519781
[TBL] [Abstract][Full Text] [Related]
9. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23.
Frishberg Y; Ito N; Rinat C; Yamazaki Y; Feinstein S; Urakawa I; Navon-Elkan P; Becker-Cohen R; Yamashita T; Araya K; Igarashi T; Fujita T; Fukumoto S
J Bone Miner Res; 2007 Feb; 22(2):235-42. PubMed ID: 17129170
[TBL] [Abstract][Full Text] [Related]
10. The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis.
Garringer HJ; Fisher C; Larsson TE; Davis SI; Koller DL; Cullen MJ; Draman MS; Conlon N; Jain A; Fedarko NS; Dasgupta B; White KE
J Clin Endocrinol Metab; 2006 Oct; 91(10):4037-42. PubMed ID: 16868048
[TBL] [Abstract][Full Text] [Related]
11. Oral Iron Replacement Normalizes Fibroblast Growth Factor 23 in Iron-Deficient Patients With Autosomal Dominant Hypophosphatemic Rickets.
Imel EA; Liu Z; Coffman M; Acton D; Mehta R; Econs MJ
J Bone Miner Res; 2020 Feb; 35(2):231-238. PubMed ID: 31652009
[TBL] [Abstract][Full Text] [Related]
12. FGF23 analysis of a Chinese family with autosomal dominant hypophosphatemic rickets.
Sun Y; Wang O; Xia W; Jiang Y; Li M; Xing X; Hu Y; Liu H; Meng X; Zhou X
J Bone Miner Metab; 2012 Jan; 30(1):78-84. PubMed ID: 21710177
[TBL] [Abstract][Full Text] [Related]
13. Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis.
Ichikawa S; Austin AM; Gray AK; Allen MR; Econs MJ
Endocrinology; 2011 Dec; 152(12):4504-13. PubMed ID: 22009723
[TBL] [Abstract][Full Text] [Related]
14. Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosis.
Garringer HJ; Malekpour M; Esteghamat F; Mortazavi SM; Davis SI; Farrow EG; Yu X; Arking DE; Dietz HC; White KE
Am J Physiol Endocrinol Metab; 2008 Oct; 295(4):E929-37. PubMed ID: 18682534
[TBL] [Abstract][Full Text] [Related]
15. FGF23 and syndromes of abnormal renal phosphate handling.
Bergwitz C; Jüppner H
Adv Exp Med Biol; 2012; 728():41-64. PubMed ID: 22396161
[TBL] [Abstract][Full Text] [Related]
16. Two novel GALNT3 mutations in familial tumoral calcinosis.
Garringer HJ; Mortazavi SM; Esteghamat F; Malekpour M; Boztepe H; Tanakol R; Davis SI; White KE
Am J Med Genet A; 2007 Oct; 143A(20):2390-6. PubMed ID: 17853462
[TBL] [Abstract][Full Text] [Related]
17. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans.
Imel EA; Peacock M; Gray AK; Padgett LR; Hui SL; Econs MJ
J Clin Endocrinol Metab; 2011 Nov; 96(11):3541-9. PubMed ID: 21880793
[TBL] [Abstract][Full Text] [Related]
18. [Phosphate metabolism and iron deficiency].
Yokoyama K
Clin Calcium; 2016 Feb; 26(2):241-9. PubMed ID: 26813504
[TBL] [Abstract][Full Text] [Related]
19. Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene.
Ichikawa S; Imel EA; Sorenson AH; Severe R; Knudson P; Harris GJ; Shaker JL; Econs MJ
J Clin Endocrinol Metab; 2006 Nov; 91(11):4472-5. PubMed ID: 16940445
[TBL] [Abstract][Full Text] [Related]
20. Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations.
Ichikawa S; Guigonis V; Imel EA; Courouble M; Heissat S; Henley JD; Sorenson AH; Petit B; Lienhardt A; Econs MJ
J Clin Endocrinol Metab; 2007 May; 92(5):1943-7. PubMed ID: 17311862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
